An economic analysis of conservative management versus active treatment for men with localized prostate cancer

Journal of the National Cancer Institute - Monographs

Volumn , Issue 45, 2012, Pages 250-257

  Perlroth, Daniella J ^a   Bhattacharya, Jay ^a   Goldman, Dana P ^b,c   Garber, Alan M ^d  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c RAND CORPORATION   (United States)

^d HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CALCULATION; CANCER LOCALIZATION; CLINICAL EFFECTIVENESS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES; COST BENEFIT ANALYSIS; COST OF ILLNESS; DISEASE COURSE; ECONOMICS; MIDDLE AGED; PROSTATE TUMOR; WATCHFUL WAITING;

ANTIANDROGEN;

AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; HEALTH EXPENDITURES; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED; WATCHFUL WAITING;

EID: 84871785533     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgs037     Document Type: Article

References (46)

1. Schoen C, Guterman S, Shih A, et al. Bending the curve: options for achieving savings and improving value in US health spending. The Commonwealth Fund Web site. http://www.commonwealthfund.org/Content/Publications/Fund-Reports/2007/Dec/Bending-the-Curve-Options-for-Achieving-Savings-and-Improving-Value-in-U-S-Health-Spending.aspx#citation. Published December 18, 2007. Accessed May 23, 2009.
2. Congressional Budget Office. Research on the comparative effectiveness of medical treatments: issues and options for an expanded federal role. Congressional Budget Office Web site. http://http://www. cbo.gov/sites/default/files/cbofiles/ftpdocs/88xx/doc8891/12-18-comparativeeffectiveness.pdf. Published December 2007. Accessed July 11, 2012.
3. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2010;103(2):117-128.
4. Institute of Medicine. Initial National Priorities for Comparative Effectiveness Research. Washington, DC: National Academies Press; 2009.
5. Altekruse SF, Kosary CL, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975-2007. National Cancer Institute Web site. http://seer.cancer. gov/csr/1975_2007/. Published 2010. Accessed July 11, 2012.
6. Fisher ES, Goodman DC, Wennberg JE. The Dartmouth atlas of health care. http://www.dartmouthatlas.org/. Accessed November 11, 2010.
7. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med. 2008;148(6):435-448.
8. Hayes JH, Ollendorf DA, Pearson SD, et al. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA. 2010;304(21):2373-2380.
9. Cooperberg MR, Broering JM, Carroll PR. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol. 2010;28(7):1117-1123.
10. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst. 2006;98(16):1134-1141.
11. Shao YH, Albertsen PC, Roberts CB, et al. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med. 2010;170(14):1256-1261.
12. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.
13. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28.
14. Joyce GF, Escarce JJ, Solomon MD, Goldman DP. Employer drug benefit plans and spending on prescription drugs. JAMA. 2002;288(14):1733-1739.
15. Joyce GF, Goldman DP, Karaca-Mandic P, Lawless GD. Impact of specialty drugs on the use of other medical services. Am J Manag Care. 2008;14(12):821-828.
16. Joyce GF, Goldman DP, Karaca-Mandic P, Zheng Y. Pharmacy benefit caps and the chronically ill. Health Aff (Millwood). 2007;26(5):1333-1344.
17. Wong YN, Freedland SJ, Egleston B, Vapiwala N, Uzzo R, Armstrong K. The role of primary androgen deprivation therapy in localized prostate cancer. Eur Urol. 2009;56(4):609-616.
18. Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173-181.
19. Potosky AL, Davis WW, Hoffman RM, et al. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the prostate cancer outcomes study. J Natl Cancer Inst. 2004;96(18):1358-1367.
20. Miller TP, Brennan TA, Milstein A. How can we make more progress in measuring physicians' performance to improve the value of care? Health Aff (Millwood). 2009;28(5):1429-1437.
21. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53(12):1258-1267.
22. Klabunde CN, Legler JM, Warren JL, Baldwin LM, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17(8):584-590.
23. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373-383.
24. SEER Stat Fact Sheets: Prostate. National Cancer Institute Web site. http://seer.cancer.gov/statfacts/html/prost.html#survival. Published 2012. Accessed July 11, 2012.
25. Horner MJ, Ries LAG, Krapcho M, Neyman N, et al, eds. SEER Cancer Statistics Review, 1975-2006. National Cancer Institute Web site. http:// seer.cancer.gov/csr/1975_2006/. Published 2009. Accessed July 11, 2012.
26. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99(20):1516-1524.
27. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110(7):1493-1500.
28. Barbash GI, Glied SA. New technology and health care costs-the case of robot-assisted surgery. N Engl J Med. 2010;363(8):701-704.
29. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR; CaPSURE Investigators. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006;106(8):1708-1714.
30. Studer UE, Whelan P, Albrecht W, et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol. 2006;24(12):1868-1876.
31. Pinkawa M, Fischedick K, Gagel B, et al. Association of neoadjuvant hormonal therapy with adverse health-related quality of life after permanent iodine-125 brachy therapy for localized prostate cancer. Urology. 2006;68(1):104-109.
32. Schellhammer PF. Timing of androgen deprivation therapy: some questions answered, others not. J Natl Cancer Inst. 2006;98(12):802-803.
33. Chodak GW, Keane T, Klotz L; Hormone Therapy Study Group. Critical evaluation of hormonal therapy for carcinoma of the prostate. Urology. 2002;60(2):201-208.
34. Loblaw DA, Mendelson DS, Talcott JA, et al; American Society of Clinical Oncology. American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer. J Clin Oncol. 2004;22(14):2927-2941.
35. Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26(4):585-591.
36. Aus G, Abrahamsson PA, Ahlgren G, et al. Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int. 2002;90(6):561-566.
37. Klotz LH, Goldenberg SL, Jewett MA, et al; Canadian Uro-Oncology Group. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170(3):791-794.
38. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38(6):706-713.
39. Soloway MS, Pareek K, Sharifi R, et al; Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167(1):112-116.
40. Pilepich MV, Winter K, John MJ, et al. Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001;50(5):1243-1252.
41. Shappley WV III, Kenfield SA, Kasperzyk JL, et al. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol. 2009;27(30):4980-4985.
42. Bill-Axelson A, Holmberg L, Ruutu M, et al; SPCG-4 Investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med. 2011;364(18):1708-1717.
43. Perlroth DJ, Goldman DP, Garber AM. The potential impact of comparative effectiveness research on U.S. health care expenditures. Demography. 2010;47(suppl):S173-S190.
44. Zeliadt SB, Ramsey SD, Penson DF, et al. Why do men choose one treatment over another? A review of patient decision making for localized prostate cancer. Cancer. 2006;106(9):1865-1874.
45. Barry MJ. Health decision aids to facilitate shared decision making in office practice. Ann Intern Med. 2002;136(2):127-135.
46. Weinberger SE. Providing high-value, cost-conscious care: a critical seventh general competency for physicians. Ann Intern Med. 2011;155(6):386-388